Document Detail

Outcome of transplantation for myelofibrosis.
MedLine Citation:
PMID:  19879949     Owner:  NLM     Status:  MEDLINE    
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.
Karen K Ballen; Smriti Shrestha; Kathleen A Sobocinski; Mei-Jie Zhang; Asad Bashey; Brian J Bolwell; Francisco Cervantes; Steven M Devine; Robert Peter Gale; Vikas Gupta; Theresa E Hahn; William J Hogan; Nicolaus Kröger; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Gary Schiller; Harry C Schouten; Vivek Roy; Peter H Wiernik; Mary M Horowitz; Sergio A Giralt; Mukta Arora
Related Documents :
16797319 - Molecular mechanisms associated with donor-specific microchimerism in peripheral blood ...
8193569 - Hla-b and -dr match reduces the allograft reaction after keratoplasty.
3303509 - Role of class i and class ii hla antigens in cadaveric renal transplantation.
12589169 - Differential immunogenicity of hla mismatches: hla-a2 versus hla-a28.
1548149 - Isolated hla-dp mismatches between donors and recipients do not influence the function ...
17445159 - Effect of hla-a2 allele disparity on clinical outcome in hematopoietic cell transplanta...
18097609 - Differences in proportion and dynamics of recipient hematopoiesis following hematopoiet...
10084769 - Cancers after stem cell transplantation in children: a cost of cure?
21348909 - Successful double lung transplantation in a patient with bilateral pulmonary and sinus ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.     Date:  2009-10-30
Journal Detail:
Title:  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation     Volume:  16     ISSN:  1523-6536     ISO Abbreviation:  Biol. Blood Marrow Transplant.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-15     Completed Date:  2010-05-28     Revised Date:  2014-06-10    
Medline Journal Info:
Nlm Unique ID:  9600628     Medline TA:  Biol Blood Marrow Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  358-67     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease-Free Survival
Graft Rejection / epidemiology
Graft Survival
Graft vs Host Disease / mortality
Hematopoietic Stem Cell Transplantation / mortality*
Histocompatibility / genetics
Kaplan-Meier Estimate
Karnofsky Performance Status
Middle Aged
Postoperative Complications / mortality
Primary Myelofibrosis / mortality*,  therapy*
Retrospective Studies
Risk Factors
Transplantation Conditioning / methods,  statistics & numerical data
Transplantation, Homologous
Treatment Outcome
Young Adult
Grant Support
5U01HL069294/HL/NHLBI NIH HHS; U24 CA076518/CA/NCI NIH HHS; U24 CA076518-14/CA/NCI NIH HHS; U24-CA76518/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chemical target and pathway toxicity mechanisms defined in primary human cell systems BioMAP systems...
Next Document:  Rapid, flow cytometric assay for NK alloreactivity reveals exceptions to rules governing alloreactiv...